{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:49:48Z","timestamp":1744174188852},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T00:00:00Z","timestamp":1335225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It has been reported that one of the serious adverse events after the treatment of oseltamivir phosphate (<jats:styled-content style=\"fixed-case\">OP<\/jats:styled-content>) for influenza patients is sudden death resulting from cardiorespiratory arrest. To investigate the aetiology of such an adverse consequence, we examined effects of <jats:styled-content style=\"fixed-case\">OP<\/jats:styled-content> (expressed as free base) on blood pressure and ventilation in anaesthetized rats with vagotomy. Intravenous <jats:styled-content style=\"fixed-case\">OP<\/jats:styled-content> (30\u2013200\u00a0mg\/kg) caused dose\u2010dependent hypotension and bradycardia in spontaneously breathing animals. Concomitantly with changes in blood pressure, the tracheal airflow increased. The ventilatory rate hastened during the injection and then transiently slowed around 1\u00a0min. after the administration (transient hypopnea). Thereafter, it gradually returned to control. The hypopnea increased with increasing dose and ventilatory arrest occurred at 200\u00a0mg\/kg. Intraduodenal <jats:styled-content style=\"fixed-case\">OP<\/jats:styled-content> (500\u20131000\u00a0mg\/kg) provoked cardioventilatory arrest 72\u2013218\u00a0min. after the injection. Oseltamivir carboxylate (100\u2013200\u00a0mg\/kg, i.v.), an active metabolite of <jats:styled-content style=\"fixed-case\">OP<\/jats:styled-content>, had no significant effect on ventilation and blood pressure. In artificially ventilated animals, intravenous <jats:styled-content style=\"fixed-case\">OP<\/jats:styled-content> caused slowing of the respiratory rate around 1\u00a0min. after the injection in a dose\u2010dependent manner. This effect of <jats:styled-content style=\"fixed-case\">OP<\/jats:styled-content> waned in 5\u00a0min. after the administration. The amplitude of phrenic nerve discharge was not changed at lower doses (30\u2013100\u00a0mg\/kg). The phrenic nerve stopped to discharge immediately after higher doses (150\u2013200\u00a0mg\/kg). We demonstrated that <jats:styled-content style=\"fixed-case\">OP<\/jats:styled-content> causes central suppression of the respiratory function in rats and suggest a relationship between the <jats:styled-content style=\"fixed-case\">OP<\/jats:styled-content>\u2010induced cardiorespiratory arrest and sudden death observed in influenza patients after taking <jats:styled-content style=\"fixed-case\">OP<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/j.1742-7843.2012.00889.x","type":"journal-article","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T14:35:12Z","timestamp":1333463712000},"page":"232-239","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["High Doses of Oseltamivir Phosphate Induce Acute Respiratory Arrest in Anaesthetized Rats"],"prefix":"10.1111","volume":"111","author":[{"given":"Satoko","family":"Kimura","sequence":"first","affiliation":[{"name":"Laboratory of Neuropharmacology School of Pharmacy Aichi Gakuin University Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Niwa","sequence":"additional","affiliation":[{"name":"Laboratory of Neuropharmacology School of Pharmacy Aichi Gakuin University Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Iwajima","sequence":"additional","affiliation":[{"name":"Laboratory of CNS Pharmacology Graduate School of Pharmaceutical Sciences Nagoya City University Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Nagano","sequence":"additional","affiliation":[{"name":"Laboratory of CNS Pharmacology Graduate School of Pharmaceutical Sciences Nagoya City University Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Laboratory of CNS Pharmacology Graduate School of Pharmaceutical Sciences Nagoya City University Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Ohi","sequence":"additional","affiliation":[{"name":"Laboratory of Neuropharmacology School of Pharmacy Aichi Gakuin University Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Maeda","sequence":"additional","affiliation":[{"name":"Laboratory of Hospital Pharmacy Graduate School of Pharmaceutical Sciences Nagoya City University  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihisa","family":"Kurono","sequence":"additional","affiliation":[{"name":"Laboratory of Hospital Pharmacy Graduate School of Pharmaceutical Sciences Nagoya City University  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ono","sequence":"additional","affiliation":[{"name":"Laboratory of CNS Pharmacology Graduate School of Pharmaceutical Sciences Nagoya City University Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Haji","sequence":"additional","affiliation":[{"name":"Laboratory of Neuropharmacology School of Pharmacy Aichi Gakuin University Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,24]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.111807"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937060-00003"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1195"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02288-1"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.09.70"},{"key":"e_1_2_5_7_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Urgent safety information for Tamiflu March 2007 http:\/\/www.info.pmda.go.jp\/kinkyu_anzen\/file\/kinkyu20070320.pdf(in Japanese)."},{"key":"e_1_2_5_8_1","unstructured":"MLHW (Ministry of Health Labor and Welfare Japan).Public opening data (documents 9\u20101) at the Meeting for Safety Measure Investigation Council held June 16 2009 http:\/\/www.mhlw.go.jp\/shingi\/2009\/06\/dl\/s0616-4ac.pdf(in Japanese)."},{"key":"e_1_2_5_9_1","unstructured":"MLHW (Ministry of Health Labor and Welfare Japan).Public opening data (documents 3\u20134) at the Meeting for Safety Measure Investigation Council held August 25 2010 http:\/\/www.mhlw.go.jp\/stf\/shingi\/2r9852000000n6tv-att\/2r9852000000n7o9.pdf(in Japanese)."},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2007.08.054"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0960327109102367"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.SC0070467"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.2220\/biomedres.29.233"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2008.04.011"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.31.638"},{"key":"e_1_2_5_16_1","unstructured":"FDA\/Center.Label Approval History Tamiflu FDA\/Center for Drug Evaluation and Research http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021087s056_021246s039lbl.pdf."},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742\u20107843.2012.00861.x"},{"key":"e_1_2_5_18_1","first-page":"1","volume-title":"Handbook of Physiology, Sect. 3, The Respiratory System, Vol. II, Control of Breathing","author":"von Euler C","year":"1986"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-60946-6_106"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(00)00059-0"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0273-2300(88)90037-2"},{"key":"e_1_2_5_22_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Public assessment report 2000 http:\/\/www.info.pmda.go.jp\/shinyaku\/shinyaku_previous_index.html(in Japanese)."},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00327-08"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2008.10.008"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.024018"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.017699"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01541-08"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.2.295"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.107.036889"},{"key":"e_1_2_5_30_1","first-page":"359","article-title":"Influence of the pro\u2010inflammatory cytokines on P\u2010glycoprotein expression and functionality","volume":"7","author":"Fernandez C","year":"2004","journal-title":"J Pharm Pharmceut Sci"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-200x.2000.01204.x"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)62043-9"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1086\/656044"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.61.10.0018"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018556"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2011.03.055"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2008.10.005"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-7843.2012.00889.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1742-7843.2012.00889.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:15:22Z","timestamp":1695500122000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-7843.2012.00889.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,24]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1111\/j.1742-7843.2012.00889.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1742-7843.2012.00889.x","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,24]]},"assertion":[{"value":"2012-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}